Skip Navigation



Annals of Oncology Advance Access published online on October 22, 2009
Annals of Oncology, doi:10.1093/annonc/mdp418
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Suzuki, R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Suzuki, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type

R. Suzuki1,*, J. Suzumiya2, M. Yamaguchi3, S. Nakamura4, J. Kameoka5, H. Kojima6, M. Abe7, T. Kinoshita8, T. Yoshino9, K. Iwatsuki10, Y. Kagami11, T. Tsuzuki12, M. Kurokawa13, K. Ito14, K. Kawa15, K. Oshimi16 and for The NK-cell Tumor Study Group

1 Department of HSCT Data Management, Nagoya University School of Medicine, Nagoya
2 Department of Internal Medicine, Fukuoka University School of Medicine, Fukuoka
3 Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu
4 Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya
5 Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai
6 Division of Hematology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba
7 First Department of Pathology, Fukushima Medical University, Fukushima
8 Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya
9 Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama
10 Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama
11 Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya
12 Department of Pathology, Nagoya Daini Red Cross Hospital, Nagoya
13 Department of Dermatology, Miyazaki University School of Medicine, Miyazaki
14 Department of Dermatology, Niigata University Graduate School of Medicine, Niigata
15 Department of Pediatrics, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka
16 Department of Hematology, Juntendo University, Tokyo, Japan

* Correspondence to: Dr R. Suzuki, Department of HSCT Data Management, Nagoya University School of Medicine, 1-1-20 Daiko-Minami, Higashi-ku, Nagoya 461-0047, Japan. Tel: +81-52-719-1974; Fax: +81-52-719-1973; E-mail: r-suzuki{at}med.nagoya-u.ac.jp

Background: Patients with natural killer (NK) cell neoplasms, aggressive NK cell leukemia (ANKL) and extranodal NK cell lymphoma, nasal type (ENKL), have poor outcome. Both diseases show a spectrum and the boundary of them remains unclear. The purpose of this study is to draw a prognostic model of total NK cell neoplasms.

Patients and methods: We retrospectively analyzed 172 patients (22 with ANKL and 150 with ENKL). The ENKLs consisted of 123 nasal and 27 extranasal (16 cutaneous, 9 hepatosplenic, 1 intestinal and 1 nodal) lymphomas.

Results: Complete remission rate for ENKL was 73% in stage I, but 15% in stage IV, which was consistent with that for ANKL (18%). The prognosis of ENKL was better than that of ANKL (median survival 10 versus 1.9 months, P < 0.0001) but was comparable when restricted to stage IV cases (4.0 months, P = 0.16). Multivariate analysis showed that four factors (non-nasal type, stage, performance status and numbers of extranodal involvement) were significant prognostic factors. Using these four variables, an NK prognostic index was successfully constructed. Four-year overall survival of patients with zero, one, two and three or four adverse factors were 55%, 33%, 15% and 6%, respectively.

Conclusion: The current prognostic model successfully stratified patients with NK cell neoplasms with different outcomes.

CD16, leukemia, lymphoma, natural killer cell, prognosis

Received for publication July 16, 2009. Accepted for publication July 22, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.